Atherosclerosis is Caesar's sword, which poses a huge risk to the present generation. Understanding the atherosclerotic disease cycle would allow ensuring improved diagnosis, better care, and treatment. Unfortunately, a highly effective and safe way of treating atherosclerosis in the medical community remains a continuous challenge. Conventional treatments have shown considerable success, but have some adverse effects on the human body. Natural derived medications or nutraceuticals have gained immense popularity in the treatment of atherosclerosis due to their decreased side effects and toxicity-related issues. In hindsight, the contribution of nutraceuticals in imparting enhanced clinical efficacy against atherosclerosis warrants more experimental evidence. On the other hand, nanotechnology and drug delivery systems (DDS) have revolutionized the way therapeutics are performed and researchers have been constantly exploring the positive effects that DDS brings to the field of therapeutic techniques. It could be as exciting as ever to apply nano-mediated delivery of nutraceuticals as an additional strategy to target the atherosclerotic sites boasting high therapeutic efficiency of the nutraceuticals and fewer side effects.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954496 | PMC |
| http://dx.doi.org/10.1080/10717544.2021.1892241 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Magnetic resonance angiography in diagnostic long-term follow-up of primary patency of the MOTIV drug-eluting bioresorbable vascular scaffold in the region below the knee: 5 years of experience.
PLoS One
January 2025
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria.
Purpose: Treatment of peripheral artery disease (PAD) in the region below the knee (BTK) is dissatisfying as failure of treated target lesions (TLF) is frequent and diagnostic imaging is often challenging. In the BTK-region metallic drug-eluting stents (mDES) yielded best results concerning primary patency (PP), but also annihilate signal in magnetic resonance angiography (MR-A). A recently introduced non-metallic drug eluting bioresorbable Tyrocore® vascular scaffold (deBVS), that offers an option for re-treatment of lesions due to its full degradation within 3-4 years after placement, was investigated with respect to its compatibility with MR-A to unimpededly depict previously treated target lesions.
View Article and Find Full Text PDFFirst-in-Man Study of a Novel Peripheral Plaque Atherectomy Device.
J Clin Hypertens (Greenwich)
January 2025
Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
This first-in-man (FIM) study evaluated the feasibility and safety of a new peripheral plaque atherectomy system in patients with symptomatic lower extremity artery disease (LEAD). Ten patients with symptomatic LEAD (Rutherford class 2-5) were enrolled in a prospective, single-center study from March to April 2024. Patients aged 18-85 years with target lesions showing ≥70% stenosis and reference vessel diameters ≥1.
View Article and Find Full Text PDFNano Delivery System for Atherosclerosis.
J Funct Biomater
December 2024
Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang 421001, China.
Atherosclerosis, a pathological process propelled by inflammatory mediators and lipids, is a principal contributor to cardiovascular disease incidents. Currently, drug therapy, the primary therapeutic strategy for atherosclerosis, faces challenges such as poor stability and significant side effects. The advent of nanomaterials has garnered considerable attention from scientific researchers.
View Article and Find Full Text PDFComputed Tomography Angiography in the Catheterization Laboratory: A Guide Towards Optimizing Coronary Interventions.
J Cardiovasc Dev Dis
January 2025
Department of Cardiology, Lausanne University Hospital and University of Lausanne, 1011 Lausanne, Switzerland.
Cardiac computed tomography (CT) has become an essential tool in the pre-procedural planning and optimization of coronary interventions. Its non-invasive nature allows for the detailed visualization of coronary anatomy, including plaque burden, vessel morphology, and the presence of stenosis, aiding in precise decision making for revascularization strategies. Clinicians can assess not only the extent of coronary artery disease but also the functional significance of lesions using techniques like fractional flow reserve (FFR-CT).
View Article and Find Full Text PDFThe Link Between Venous and Arterial Thrombosis: Is There a Role for Endothelial Dysfunction?
Cells
January 2025
Department of Medical Biotechnologies and Translational Medicine, University of Milan, 20125 Milan, Italy.
Venous thromboembolism (VTE) and arterial thrombosis (AT) are distinct yet closely related pathological processes. While traditionally considered separate entities, accumulating evidence suggests that they share common risk factors, such as inflammation and endothelial dysfunction (ED). This review explores the parallels and differences between venous and arterial thrombosis, with particular attention to the role of unprovoked VTE and its potential links to atherosclerosis and systemic inflammation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!